Reproductive Medicine Associates of New Jersey, Department of Reproductive Endocrinology, Basking Ridge, New Jersey 07920, USA.
Fertil Steril. 2013 Sep;100(3):718-24. doi: 10.1016/j.fertnstert.2013.04.043. Epub 2013 May 30.
To determine how often trophectoderm biopsy and rapid, real-time quantitative polymerase chain reaction (PCR)-based comprehensive chromosome screening (CCS) alters clinical management by resulting in the transfer of a different embryo than would have been chosen by traditional day 5 morphology-based criteria.
Prospective.
Academic center for reproductive medicine.
PATIENT(S): Infertile couples (n = 100; mean age 35 ± 4 years) with at least two blastocysts suitable for biopsy on day 5.
INTERVENTION(S): Prior to trophectoderm biopsy for CCS the embryologist identified which embryo would have been selected for traditional day 5 elective single ET.
MAIN OUTCOME MEASURE(S): The risk of aneuploidy in the embryos that would have been selected on day 5 was calculated and compared with the aneuploidy rate of the cohort of all embryos that underwent CCS testing. The aneuploidy risk was compared between age groups.
RESULT(S): After quantitative PCR-based CCS, 22% (95% confidence interval 15%-31%) of the embryos selected by day 5 morphology were aneuploid, which was lower than the 32% aneuploidy rate of the cohort. Patients ≥35 years had a higher risk of an aneuploid blastocyst being selected by morphology than those <35 years old (31% vs. 14%). Among patients who had selection altered by CCS, 74% (14/19) delivered, including 77% (10/13) after elective single ET. Most patients (77%) had an additional euploid blastocyst vitrified for future use.
CONCLUSION(S): The CCS results alter embryo selection due to the presence of aneuploidy in embryos with optimal day 5 morphology. Excellent outcomes were obtained when CCS-based selection was different than morphology-based selection.
确定滋养层活检和快速实时定量聚合酶链反应(PCR)为基础的全面染色体筛查(CCS)改变临床管理的频率,其结果是转移不同于传统第 5 天形态学标准选择的胚胎。
前瞻性。
生殖医学学术中心。
有至少 2 个适合第 5 天活检的囊胚的不孕夫妇(n = 100;平均年龄 35 ± 4 岁)。
在进行 CCS 活检前,胚胎学家确定了哪些胚胎将被选择用于传统的第 5 天选择性单胚胎移植(ET)。
计算在第 5 天被选择的胚胎的非整倍体风险,并与所有接受 CCS 检测的胚胎的整倍体率进行比较。比较了不同年龄组之间的非整倍体风险。
在基于定量 PCR 的 CCS 之后,通过形态学选择的 22%(95%置信区间 15%-31%)的胚胎是非整倍体,低于整倍体率为 32%的队列。年龄≥35 岁的患者通过形态学选择非整倍体囊胚的风险高于年龄<35 岁的患者(31% vs. 14%)。在 CCS 改变胚胎选择的患者中,74%(14/19)分娩,包括 77%(10/13)后进行选择性单 ET。大多数患者(77%)有一个额外的整倍体囊胚被冷冻以备将来使用。
CCS 结果改变了胚胎选择,因为在具有最佳第 5 天形态的胚胎中存在非整倍体。当 CCS 选择与形态学选择不同时,获得了良好的结果。